Browse Neurology Alert Articles by Topic

Leriglitazone for the Treatment of Adrenomyeloneuropathy

A 96-week trial of leriglitazone to slow the progression of symptoms in adrenomyeloneuropathy did not meet the primary endpoint. However, post-hoc analyses revealed a beneficial effect in patients treated earlier in their disease course.

Self-Treatment of Recurrent Benign Paroxysmal Positional Vertigo

Using a cell phone-based app, self-treatment of recurrent benign positional paroxysmal vertigo was feasible and effective in most patients.

A Population-Based Study of Progressive Multifocal Leukoencephalopathy

In this population-based cohort study of 584 cases of progressive multifocal leukoencephalopathy (PML), predisposing conditions with the highest risk of PML were human immunodeficiency virus (HIV) infection, hematological malignancies, chronic inflammatory disease, solid organ transplantation, solid malignancies, and primary immune deficiency. The one-year mortality rate was 38.2% for all cases of PML. Factors independently associated with higher mortality rate were older age, male gender, and immunosuppressive diseases, such as hematological malignancies, solid neoplasms, and HIV.

Long-Term Air Pollution Exposure Could Raise Risk for Depression, Anxiety

Two research groups reported on breathing dirty air and how that affects mental health.

Cumulative Estrogen Exposure Linked to Lower Stroke Risk

These findings could help clinicians sustain their postmenopausal patients’ neurological health.

Efficacy and Safety of Leriglitazone in Patients with Friedreich Ataxia

Friedreich ataxia (FRDA) is an autosomal, recessive, multisystemic disease characterized by progressive weakness, ataxia, and dysarthria starting in childhood and resulting in severe morbidity and premature death. There are no approved treatments for FRDA. With recent preclinical studies suggesting potential benefit of PPARPγ agonists in motor function and reduced radiographic disease activity, the current study explores the effect of leriglitazone, a PPARPγ agonist, in patients with moderate to severe FRDA.

Late-Onset Pompe Disease: A Review of Clinical Features

In this systematic literature review of studies that evaluate motor and locomotion function in patients with adult, late-onset Pompe disease, the clinical spectrum reveals weakness of respiratory, axial, and proximal limb muscles.

Can a Blood-Based Test Serve as a Biomarker for Parkinson’s Disease?

This proof-of-concept study proposes that a noninvasive assay detecting pathology-associated α-synuclein extracted from blood may reveal a reliable biomarker for Parkinson’s disease.

Do Spinal Cord Stimulators Really Help for Chronic Pain?

A comprehensive analysis of a large clinical database regarding treatment of patients with chronic low back pain did not support the benefit of spinal cord stimulators compared to conventional medical management for chronic pain.

Magnetic Brain Stimulation for Alzheimer’s Disease

Transcranial magnetic stimulation, targeted at the precuneus in an effort to maintain a normal default mode network, shows some promise in slowing cognitive decline and maintaining normal electrophysiology in patients with mild to moderate Alzheimer’s disease.